Mativ (NYSE:MATV) Downgraded by Zacks Research to "Hold"

Key Points

• Mativ was downgraded by Zacks Research from a "strong-buy" rating to a "hold" rating, reflecting a negative shift in sentiment among analysts.
• The stock has experienced significant price fluctuations, with a 12-month low of $4.34 and a high of $17.47, and it currently trades around $10.68.
• Institutional investors continue to increase their stakes in Mativ, indicating strong institutional interest, with nearly 95% of the stock owned by hedge funds and other entities.

Mativ (NYSE:MATV - Get Free Report) was downgraded by equities researchers at Zacks Research from a "strong-buy" rating to a "hold" rating in a note issued to investors on Tuesday,Zacks.com reports.

Other equities analysts have also recently issued research reports about the stock. Wall Street Zen raised shares of Mativ from a "hold" rating to a "buy" rating in a research report on Saturday, August 9th. Weiss Ratings restated a "sell (d-)" rating on shares of Mativ in a report on Wednesday. One investment analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of "Hold" and an average price target of $10.00.

Mativ Stock Down 0.6%

Shares of MATV opened at $10.68 on Tuesday. Mativ has a 12 month low of $4.34 and a 12 month high of $17.47. The company has a current ratio of 2.37, a quick ratio of 1.21 and a debt-to-equity ratio of 2.65. The stock's 50-day moving average price is $11.14 and its two-hundred day moving average price is $7.88. The company has a market capitalization of $583.88 million, a PE ratio of -1.28 and a beta of 0.83.

Mativ (NYSE:MATV - Get Free Report) last released its earnings results on Wednesday, August 6th. The company reported $0.33 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.18 by $0.15. Mativ had a negative net margin of 23.09% and a positive return on equity of 4.12%. The business had revenue of $525.40 million for the quarter, compared to analyst estimates of $505.00 million. On average, analysts anticipate that Mativ will post 1.15 EPS for the current year.

Institutional Investors Weigh In On Mativ

Institutional investors have recently added to or reduced their stakes in the business. GAMMA Investing LLC raised its holdings in Mativ by 119.7% during the 1st quarter. GAMMA Investing LLC now owns 4,462 shares of the company's stock valued at $28,000 after acquiring an additional 2,431 shares during the period. QRG Capital Management Inc. purchased a new position in Mativ during the 1st quarter valued at about $64,000. Hsbc Holdings PLC increased its position in shares of Mativ by 61.2% during the first quarter. Hsbc Holdings PLC now owns 38,828 shares of the company's stock valued at $242,000 after buying an additional 14,734 shares during the period. Cubist Systematic Strategies LLC lifted its holdings in shares of Mativ by 84.6% in the first quarter. Cubist Systematic Strategies LLC now owns 223,364 shares of the company's stock worth $1,392,000 after buying an additional 102,376 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. boosted its position in shares of Mativ by 9.4% in the first quarter. Charles Schwab Investment Management Inc. now owns 751,405 shares of the company's stock valued at $4,681,000 after acquiring an additional 64,265 shares during the period. 94.95% of the stock is owned by hedge funds and other institutional investors.

Mativ Company Profile

Mativ Holdings, Inc, together with its subsidiaries, manufactures and sells specialty materials in the United States, Europe, the Asia Pacific, the Americas, and internationally. The company operates through two segments, Advanced Technical Materials and Fiber-Based Solutions. The Advanced Technical Materials manufactures and sells various engineered polymer, resin and fiber-based substrates, nets, films, adhesive tapes, and other nonwovens for the filtration, protective solutions, release liners, and healthcare end-markets.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.